Galapagos increases share capital through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 25 September 2014 - Galapagos NV (Euronext: GLPG) announced
today a share capital increase arising from warrant exercises.
Since its inception in 1999, Galapagos has used warrant plans to incentivize
personnel and management and have them share in the success of the company.
Following warrant exercises during the exercise period from 3 September 2014
through 16 September 2014, Galapagos issued 12,260 new ordinary shares for a
total capital increase (including issuance premium) of ?130,003.92. No members
of the Board of Directors or Executive Committee exercised warrants.
To date, Galapagos' total share capital amounts to ?163,868,834.64; the total
number of securities conferring voting rights is 30,292,604, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 2,899,718, which equals the total number of voting rights that may
result from the exercise of these warrants (but excludes the 666,760 warrants of
Warrant Plan 2014 which were created on 25 July 2014 subject to acceptances).
Galapagos does not have any convertible bonds or shares without voting rights
outstanding.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline comprising three Phase 2 studies, two Phase 1 studies,
five pre-clinical, and 20 discovery small-molecule and antibody programs in
cystic fibrosis, inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and Galapagos signed an
agreement for the development and commercialization of GLPG0634. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. Galapagos has another
selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by
GlaxoSmithKline in 2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program has completed a
Proof-of-Concept Phase 2 study. GLPG1205 is a first-in-class molecule that
targets inflammatory disorders and has completed Phase 1. GLPG1690 is a first-
in-class compound that targets pulmonary diseases and is currently in a Phase 1
study. AbbVie and Galapagos signed an agreement in cystic fibrosis to develop
and commercialize molecules that address mutations in the CFTR gene.
Potentiator GLPG1837 is at the pre-clinical candidate stage. The Galapagos
Group, including fee-for-service subsidiary Fidelta, has around 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1858013]
Unternehmensinformation / Kurzprofil:
Datum: 25.09.2014 - 18:00 Uhr
Sprache: Deutsch
News-ID 342336
Anzahl Zeichen: 5385
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 110 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos increases share capital through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
